Impaired Kidney Function Portended a Bleak Prognosis for Surgically Treated Hypertensive Intracerebral Hemorrhage Patients

Jian Wang, Rui Wang, Hu Qin^{1#}, Lei Zuo[#]

Departments of Trauma Intensive Care Unit and ¹Neurosurgery, First Affiliated Hospital, Xinjiang Medical University, Urumqi 830011, China *These authors are responsible for this study.

Abstract

Purpose: Spontaneous intracerebral hemorrhage (ICH) cases caused by hypertension often have poor prognoses. The use of dehydrant agents, such as mannitol, is common to reduce intracranial pressure and alleviate cerebral edema, but they may also pose a risk of worsening kidney function. This study aimed to investigate the impact of impaired kidney function on the outcomes of surgically treated hypertensive ICH patients. Methods: We conducted a retrospective analysis of a consecutive cohort of patients who underwent surgical intervention due to hypertension-related ICH at our institute between December 1, 2017, and January 31, 2022. Demographic, clinical, radiological, and prognostic data were collected. Patients were categorized into two groups based on 90-day mortality: group A [overall survival (OS) \leq 3 months] and group B (OS >3 months). Survival analysis was performed to identify factors associated with poor outcomes. Results: Among the 232 eligible patients, group A exhibited significantly impaired kidney function, as indicated by mean estimated glomerular filtration rate (eGFR) at admission, postoperative, 3-day postoperative, and 7-day postoperative time points (91.9, 82.5, 73.5, 75.2 ml/min/1.73 m²). In contrast, group B did not show significant changes in kidney function (mean eGFR for the corresponding time points: 108.1, 106.5, 111.5, 109.6 ml/min/1.73 m²). The 3-day postoperative eGFR showed the strongest predictive ability for assessing prognosis [areas under the curve (AUC): 0.617, 0.675, 0.737, 0.730]. Univariate and multivariate analyses identified low Glasgow Coma Scale (GCS) score (3-8), ventricle intrusion of hematomas, cardiac failure, larger hematoma volume, infection, and lower 3-day postoperative eGFR as adverse factors for survival. Conclusions: Preserving kidney function is crucial for achieving favorable outcomes in hypertensive ICH cases. Impaired 3-day postoperative eGFR emerged as an independent risk factor for overall survival. Patients with cardiac failure, infection, and larger hematoma volume should receive careful management to improve outcomes.

Keywords: Hypertension, intracerebral hemorrhage, kidney function, prognosis

INTRODUCTION

Spontaneous intracerebral hemorrhage (ICH) is a highly acute and often fatal type of stroke that poses a significant threat to the quality of life and life expectancy, particularly among aging individuals.^[1] The increasing elderly population has led to a substantial rise in the incidence of ICH, with an annual rate of 12–15 cases per 100,000 individuals.^[2-6] The high morbidity, disability, and mortality associated with ICH present a formidable challenge for physicians and families alike.

Hypertension is closely linked to more than 50–70% of spontaneous ICH cases.^[7] Prolonged hypertension can cause structural changes in small arteries and perforator vessels, resulting in irreversible degeneration. These abnormal vessels are often implicated in ICH occurrences, affecting regions such as the basal ganglia, thalamus, brainstem, and cerebellum. Factors such as aging, alcohol consumption, smoking, and drug use can directly contribute to uncontrolled hypertension, ultimately leading to ICH.^[8,9] Critical treatment modalities for ICH include hematoma removal through surgical intervention, blood pressure reduction, and cerebral edema alleviation, which are vital for saving lives and improving outcomes.^[2,4]

However, controversies exist regarding blood pressure reduction and the use of dehydration therapy with mannitol due to potential kidney damage.^[10] Rapid blood pressure reduction may result in inadequate blood supply to the peripheral circulation, while long-term use of dehydrating agents can impose an additional burden on the kidneys,

Address for correspondence: Dr. Hu Qin, Department of Neurosurgery, First Affiliated Hospital, Xinjiang Medical, University, No.1 Liyu Mountain Road, Xinqu District, Urumqi – 830011, China. E-mail: Qinhu86@163.com Dr. Lei Zuo, Department of Trauma Intensive Care Unit, First Affiliated Hospital, Xinjiang Medical University, No.1 Liyu Mountain Road, Xinqu District, Urumqi 830011, China. E-mail: 18999124558@163.com

Submitted: 05-Mar-2023 Revised: 20-Jun-2023 Accepted: 13-Aug-2023 Published: 11-Sep-2023

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com DOI: 10.4103/aian.aian_195_23

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

exacerbating compromised kidney function in advanced patients.^[11] Preserving optimal kidney function may help patients navigate the most critical period and achieve more favorable prognoses.^[12] Nonetheless, the precise impact of kidney function on the prognosis of ICH patients remains insufficiently explored.

Therefore, in this retrospective study, we conducted a comprehensive evaluation of ICH patients treated in the intensive care unit (ICU) to investigate the relationship between kidney function and prognosis. By elucidating this association, our findings may contribute to the development of tailored therapeutic protocols that strike a balance between kidney function and the prognosis of ICH patients.

Methods and Materials

Study design and patient selection

This study retrospectively included a consecutive cohort of patients who experienced ICH due to hypertension and were admitted to the Trauma ICU at the First Affiliated Hospital, Xinjiang Medical University, between December 1, 2017, and January 31, 2022. Specifically, all patients in our study presented with intracranial hematoma and met the surgical intervention criteria as follows: 1) for supratentorial hematoma: hematoma volume >20 m, evidence of increased intracranial pressure on imaging, such as midline structure displacement >5 mm, obstruction of more than 1/2 of the ipsilateral lateral ventricle, and blurring or disappearance of the ipsilateral cisterns and sulci, or intracranial pressure (ICP) >25 mmHg; 2) for cerebroventricular hemorrhage: large hematoma volume exceeding 50% of the lateral ventricle, Glasgow Coma Scale (GCS) <8 points, obstructive hydrocephalus, or significant intracranial hypertension; 3) for infratentorial hematoma: hematoma diameter >3 cm or volume >10 ml, fourth ventricle compression or complete occlusion, significant space-occupying effect and intracranial hypertension, evidence of brain herniation (occipital foramen herniation is the main type, or significant obstructive hydrocephalus; 4) for brainstem hemorrhage: hematoma volume >5 ml and relatively concentrated, GCS score <8, accompanied by progressive deterioration of neurological function, unstable vital signs, especially significant central blood pressure, body temperature, and breathing abnormalities appearing early in bleeding, or strong willingness from family members to undergo surgery. Patients with the following criteria were excluded from the study: 1subarachnoid hemorrhage or aneurysm (27 cases), (2) ICH due to moyamoya disease (2 cases), amyloidosis (1 case), or arteriovenous malformation (7 cases), (3) recent history of trauma (1 case), and (4) patients with malignancies or other terminal diseases (3 cases) or loss of follow-up (5 cases). Demographic, clinical, radiological, and prognostic information of the finally qualified 232 cases was collected for further analysis. The study protocol was approved by the Institutional Review Board of Xinjiang Medical University, in accordance with the principles of the Declaration of Helsinki, and written informed consent was waived by the Institutional Review Board.

Radiological data

For patients suspected of having ICH, head non-contrast computerized tomography (CT) scans were performed in the emergency room using a GE Discovery CT750HD machine (USA) with the following parameters: 120 kV, 400 mA, slice thickness of 5 mm, and a gap of 2.5 mm. These scans were used to determine the location and volume of the hematomas. The location of the hematoma was categorized into the cerebral hemisphere, basal ganglia/thalamus, ventricle, or infratentorial structures (brainstem or cerebellum) based on the geographic epicenter of the hemorrhage. Hemorrhage volumes were measured using a computerized planimetric method and the simplified formula for the volume of an ellipsoid, ABC/2, where A represents the largest diameter of the hemorrhage, B represents the largest diameter 90° to A on the same slice, and C represents the approximate number of 2-mm slices.^[13]

Estimated glomerular filtration rate (eGFR) tests

The serum creatinine level was measured at the time of hospital admission, postoperative, 3-day postoperative, and 7-day postoperative to determine the estimated glomerular filtration rate (GFR). The estimated GFR was calculated using the abbreviated Modification of Diet in Kidney Disease formula proposed by the Modification of Diet in Kidney Disease Study Group: eGFR (ml/minute per 1.73 m²) = $186 \times [\text{serum}]$ creatinine] - 1.154 × age - 0.203× [0.742 if female]. Patients without chronic kidney disease (CKD) from the Get with the Guidelines Intracerebral Hemorrhage (GWTG-ICH) database, with an eGFR>90, were used as the referent group for comparison. Patients were then categorized according to the degree of kidney dysfunction (eGFR in ml/minute per 1.73 m²) using modified definitions from the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative clinical practice guidelines: normal (eGFR \geq 90), mild (60 \leq eGFR <90), moderate ($30 \le eGFR < 60$), ($15 \le eGFR < 30$), and kidney failure (eGFR <15).[14,15]

Treatment protocol and follow-up

The decision-making process for ICH management was outlined in detail [Figure 1a].^[16,17] All patients underwent surgical intervention to remove the intracranial hematoma timely. Eligible patients received dehydrant agents such as mannitol, furosemide, and glycerin fructose to alleviate cerebral edema. The highest permissible creatinine level for administering mannitol in our study group was <133 umol/ml (or eGFR >80 ml/min). For patients with creatinine levels ranging between 133 and 177 umol/l (or eGFR 50-80 ml/min), a reduced dose of mannitol was administered. Mannitol was contraindicated for patients with creatinine levels >177 umol/l (or eGFR <50 ml/min). Additionally, it is important to note that the treatment protocol for anti-edema measures, including mannitol, furosemide, glycerin fructose, and 3% NaCl, was dynamic and adjusted based on the individual patient's condition and creatinine levels. The dosages and combinations of these medications were tailored to the specific needs of each patient. The administration



Figure 1: Treatment of ICH patients and outcomes. (A) the decision-making procedure in ICH management. (B-D) three representative hypertensive ICH cases who received evacuation of hematoma, a for preoperative and b for postoperative CT images

of these agents was carried out under the guidance of two senior physicians. Ventilatory support was performed for sedated patients by volume-synchronized intermittent mandatory ventilation (V-SIMV) or pressure-synchronized intermittent mandatory ventilation (P-SIMV). For patients who were spontaneously breathing, we employed continuous positive airway pressure (CPAP) or pressure support ventilation (PSV). Antiepileptic drugs (such as midazolam, sodium valproate, phenobarbital sodium) and anti-infective agents (like cephalosporin, vancomycin, meropenem) were prescribed to eligible patients. Any other complications that arose during the treatment were duly managed by the medical team.

Follow-up and outcome assessment

For patients who passed away during their hospital stay, the cause of death was determined based on clinical documentation, including medical records, physician notes, and autopsy reports, if available. Secondly, for patients who died after discharge, the cause of death was obtained through a thorough review of their medical records, including follow-up information, death certificates, and relevant clinical information from primary care providers or other healthcare facilities. Telephone follow-up was conducted every 3–4 months or as clinically indicated to monitor the patients' progress. The overall survival (OS) was defined as the duration between admission and either the date of death or the last follow-up.

Statistical analysis

Statistical analysis was performed using appropriate methods. Continuous variables were analyzed using the student's *t*-test, while nonparametric data were analyzed using the Mann– Whitney U-test. Categorical variables were compared using the Chi-square test or Fisher's exact test. Receiver operating characteristic (ROC) curves were constructed to determine the AUC and the optimal cutoff value using the Youden index (sensitivity + specificity -1) with the pROC package in R. GraphPad Prism (Version 8.0.1, GraphPad Software, USA), R (version 4.0.3, USA), and R Studio (Version 1.2.5033, USA) were used for statistical analyses. The survival rate of patients was estimated using Kaplan-Meier plots, and differences between survival curves were compared using the log-rank test. Patients who underwent surgical intervention due to hypertension-related ICH group were further divided into subgroups based on the prognosis: inferior and favorable, with a cutoff of 3 months for overall survival. Cox proportional hazard regression models were constructed to estimate the hazard ratio (HR) for each potential prognostic factor. A nomogram incorporating the most important features was generated, and calibration curves were used to reduce overfitting bias. Decision curve analysis (DCA) was also applied to assess the value of the model, including the most important features. Two-sided tests were used to calculate probability values, and statistical significance was defined as *P* < 0.05.

RESULTS

Demographic, clinical, and radiological information of patients who underwent surgical intervention due to hypertension-related ICH cases

A total of 232 qualified patients who underwent surgical intervention due to hypertension-related ICH cases were included in our study. Among them, 97 (41.8%) patients passed away within 3 months and were categorized as group A, while the remaining 135 (58.2%) cases showed relatively favorable prognoses and were assigned to group B. The distribution of gender and age between the deceased and surviving subgroups was comparable (all P > 0.05, Table 1).

Table 1: Clinical	and radiological	characteristics of	i patients v	who underwent	surgical	intervention	due	to
hypertension-rela	ated ICH							

Characteristics Group A (0S ≤ 3 moths) P 135 Gendar (n, %) 97 135 5 Fenala 28 (28.9) 44 (32.6) 0.545 Mala 69 (71.1) 91 (67.4) 28 (28.9) 44 (32.6) 0.545 Admission CCS 6.043.1 9.143.5 0.002 2.029 0.002 Admission CCS 6.043.1 9.143.5 0.001 0.002 2.020 0.002 Locatino (n, %) T 2.020 3.3.3425.1 0.002 0.001 Basel agnita/halmus 2.4 (24.7) 47 (34.8) Variancie immaian 51 (52.6) 34 (25.2) Infractornal structure 9 (9.3) 11 (8.1) 0.002 Variancie immaian 51 (52.6) 34 (25.2) 10.653 0.158 No 1.55 0.158 No 0.158 No 0.158 No 1.55 0.165 No 1.55 0.165 No 1.55 0.015 No 1.55 0.763 0.168 No 1.55 0.763 0.168				
Number of cases (n)97135Female28 (28.9)44 (32.6)0.545Male69 (71.1)91 (67.4).Age (nean, ys)59.112.860.115.30.829Admission GCS6.043.19.143.50.001Volume (mean, ml) of ICH52.83-11.833.32-25.10.002Leastion (n, %)Cerebral hemisphere13 (13.4)43 (31.9).0.001Baad ganghi/haharans24 (24.7)47 (34.8).Ventricle intrusion51 (52.6)34 (25.2).Infraetonial structure9 (9.3)11 (8.1).Obesity (n, %)Yes15 (15.5)13 (12.30)0.158.No82 (84.5)104 (77.0)Upertensive crisis (n, %)Yes9 (9.3)19 (44.1).0.269.No88 (90.7)116 (85.9)Time for surgery (median, hours)3.73.5.0.763Daration of ventilatory support (median, days)8.53.5.0.763Daration of ventilatory support (median, days)8.7.3.7Yes10 (10.3)13 (8.9).0.714.No48 (49.5)106 (78.5)Yes0.020611 (8.1).0.001No10 (10.3)13 (8.9).0.714 <trr>No10 (20.6)11 (8.1)</trr>	Characteristics	Group A (OS \leq 3 months)	Group B (OS >3 months)	Р
Gender (n, %0) 28 (28.9) 44 (32.6) 0.545 Male 69 (71.1) 91 (67.4) 2 Admission GCS 60.63.1 9.143.2 0.6001 Volume (mean, ml) of ICH 52.8431.8 33.3425.1 0.002 Leadmin (mean, ml) of ICH 52.8431.8 33.3425.1 0.002 Basal ganglin/fihalamas 24 (24.7) 47 (14.8) 2 Ventricle intrusion 15 (15.5) 31 (23.0) 0.158 No 28 (84.5) 100 (70.0) 2 Yes 15 (15.5) 31 (23.0) 0.158 No 28 (45.5) 100 (70.0) 2 Yes 35 (34.6) 86 (63.7) 0.168 No 28 (45.7) 1.61 (85.9) 2 Dabets (n, %0) 3.5 0.703 3.5 0.703 Darden (Nems) 8.7 3.5 0.703 No 88 (90.7) 116 (85.9) 2 Darden (Nems) 8.7 3.5 0.703 No 84 (45.5) 106 (78.5)<	Number of cases (<i>n</i>)	97	135	
Female 28 (28 9) 44 (26) 0.54 Male 69 (71.1) 91 (67.4) 0.829 Admission GCS 6.043.1 9.143.3 0.000 Ventor (men, mt) of ICH 5.28.431.8 33.32.25.1 0.000 Lecation (n, %) 7 74.34.8 74.000 Dessity (m, %) 24 (24.7) 47.(34.8) 74.000 Ventricle intrusion 51 (52.6) 34 (25.2) 74.000 Dessity (m, %) 7 74.34.8 74.000 Ventricle intrusion 51 (52.6) 34 (25.0) 0.165 No 82 (44.5) 104 (77.0) 75.000 Vestity (m, %) 7 74.34.9 75.000 Vestity (m, %) 82 (44.5) 104 (77.0) 76.000 No 82 (90.7) 116 (85.9) 76.000 No 82 (90.7) 116 (Gender $(n, \%)$			
Male 60 (71.1) 91 (74.) Age (mean, mt) of ICH 59.1+12.8 60.1+13.2 0.829 Admission GCS 6.04.3.1 9.1±3.5 <0.001	Female	28 (28.9)	44 (32.6)	0.545
Age (mean, yn) 59.141.2.8 60.141.3.2 0.829 Admission GCS 6.043.1 9.143.5 <0.001	Male	69 (71.1)	91 (67.4)	
Admission GCS 6.62.1.1 9.12.5.2 <0.000	Age (mean, yrs)	59.1±12.8	60.1±13.2	0.829
Volums (mean, m) of ICH 52,8431.8 33,3425.1 0.002 Location (n, %)	Admission GCS	6.0±3.1	9.1±3.5	< 0.001
Lacation (n, %) Carabara hemisphere 13 (13, 14) 43 (31.9) <0.001 Basal agnifuthalmuus 24 (24.7) 47 (34.8) Ventricle intrusion 51 (52.6) 34 (25.2) Infrateotrical structure 9(9.3) 11 (8.1) Obesity (n, %) Ves 15 (5.5) 31 (23.0) 0.158 No 26 (45.5) 104 (77.0) Hypertensive crisis (n, %) Yes 36 (63.7) 0.165 No 44 (45.4) 49 (36.3) Diabetes (n, %) Yes 9(9.3) 116 (85.9) Time for sargery (median, hours) 3.7 3.5 0.001 Postoperative sciures (%) No 88 (90.7) 116 (85.9) Time for sargery (median, hours) 3.7 3.5 0.001 Postoperative sciures (%) Yes 0 9 (9.5) 3.5 0.001 Postoperative sciures (%) Yes 0 10 (10.3) 13 (8.9) 0.714 No 88 (90.7) 122 (91.1) Infection Yes 0 49 (50.5) 29 (21.5) <0.001 Postoperative sciures (%) No 77 (79.4) 122 (91.1) Infection Yes 0 20 (20.6) 11 (8.1) 0.0006 No 77 (79.4) 124 (91.9) Cardiac fullure (n, %) Yes 0 20 (20.6) 11 (8.1) 0.0001 No 6CFR 0 20 (20.6) 11 (8.1) 0.0001 No 77 (79.4) 124 (91.9) Cardiac fullure (n, %) Yes 0 20 (20.6) 11 (8.1) 0.0001 No 77 (79.4) 124 (91.9) Cardiac fullure (n, %) Yes 0 20 (20.6) 11 (8.1) 0.0001 No 77 (79.4) 124 (91.9) FOC (minlg) 3.61 #7.3 3.61 #7.0 0.001 Postoperative cGFR 7.52 ±54.2.2 106.51 #0.51 *0.001 Postoperative cGFR 7.52 ±54.2.2 106.51 *0.001 Postoperative cGFR 7.52 ±54.2.7 *0.001 Postop	Volume (mean, ml) of ICH	52.8±31.8	33.3±25.1	0.002
Cerebral hemisphere 13 (1.4) 43 (31.9) <0.001	Location $(n, \%)$			
Basel ganglin/hulamus 24 (24.7) 47 (34.8) Ventricle intrusion 51 (52.6) 34 (25.2) Infratentrial structure 9 (9.3) 11 (8.1) Obesity (n, %) 15 (15.5) 31 (23.0) 0.158 No 82 (84.5) 104 (77.0) 105 Hypertensive crisis (n, %) 33 (54.6) 86 (63.7) 0.165 No 44 (45.4) 49 (36.3) 268 Diabetes (n, %) 116 (65.9) 268 No 88 (90.7) 116 (65.9) 260 Duration of ventilatory support (median, hours) 8.5 3.5 0.001 No 87 (87.7) 13 (8.9) 0.714 No 87 (97.7) 122 (91.1) 106 (78.5) Yes 10 (10.3) 13 (8.9) 0.001 No 87 (97.7) 122 (91.1) 0.001 No 87 (97.7) 122 (91.1) 0.001 No 70 (20.6) 11 (8.1) 0.001 No 70 (20.6) 11 (8.1) 0.001 </td <td>Cerebral hemisphere</td> <td>13 (13.4)</td> <td>43 (31.9)</td> <td>< 0.001</td>	Cerebral hemisphere	13 (13.4)	43 (31.9)	< 0.001
Verticle intrusion \$1 (52.6) 34 (25.2) Infratentorial structure 9 (9.3) 11 (8.1) Ves 15 (15.5) 31 (23.0) 0.158 No 85 (84.5) 104 (77.0) 104 Hypertensive crisis (n, %) 32 (84.5) 104 (77.0) 105 No 44 (45.4) 49 (36.3) 106 (37.2) Diabetes (n, %) 37.7 3.5 0.763 Diartes (n, four) 3.7 3.5 0.763 Duration of ventilatory support (median, days) 8.5 3.5 0.001 Postoperative seizures (%) 122 (91.1) 122 (91.1) 116 (85.9) Infection Yes 10 (10.3) 13 (8.9) 0.714 No 87 (89.7) 122 (91.1) <0.001	Basal ganglia/thalamus	24 (24.7)	47 (34.8)	
Infratentorial structure 9 (9.3) 11 (8.1) Obesity (n, %)	Ventricle intrusion	51 (52.6)	34 (25.2)	
Obesity $(n, \frac{n}{6})$ Yes 15 (15.5) 31 (23.0) 0.158 No 82 (84.5) 104 (77.0) Hypertensive crisis $(n, \frac{n}{6})$ 43 (45.4) 49 (36.3) Diabetes $(n, \frac{n}{6})$ 44 (45.4) 49 (36.3) Diabetes $(n, \frac{n}{6})$ 88 (90.7) 116 (85.9) Time for surgery (median, hours) 3.7 3.5 0.763 Duration of ventilatory support (median, days) 8.5 3.5 0.001 Postoperative seizures (%) 7(89.7) 122 (91.1) Yes 9 (50.5) 29 (21.5) <0.001	Infratentorial structure	9 (9.3)	11 (8.1)	
Yes15 (15.5)31 (23.0)0.158No82 (84.5)104 (77.0)Hypertensive crisis (n, %)82 (84.5)04 (75.0)Yes53 (54.6)86 (63.7)0.165No44 (45.4)49 (36.3)0Diabetes (n, %)9 (9.3)19 (14.1)0.269No88 (90.7)116 (85.9)0Time for surgery (median, hours)3.73.50.763Duration of ventilatory support (median, days)8.53.50.001Postoperative seizures (%)7122 (91.1)114No87 (89.7)122 (21.1)0.011Infection7122 (91.1)0.001No84 (49.5)106 (78.5)2001No77 (79.4)124 (91.9)0.001No77 (79.4)124 (91.9)0.001Postoperative cGFR9.544.71108.1445.7<0.001	Obesity $(n, \%)$			
No 82 (84.5) 104 (77.0) Hypernexive crisis (n, %)	Yes	15 (15.5)	31 (23.0)	0.158
Hypertensive crisis $(n, \%)$ Yes 53 (54.6) 86 (63.7) 0.165 No 44 (54.3) 49 (36.3) 10 Diabetes $(n, \%)$ Yes 9 (9.3) 19 (14.1) 0.269 No 88 (90.7) 116 (85.9) 10 10.10 13 (85.9) 10 Time for surgery (median, hours) 3.7 3.5 0.001 Postoperative seizures (%) 7 3.5 0.001 Postoperative seizures (%) 8.5 3.5 0.001 Postoperative seizures (%) 7 3.5 0.001 No 87 (89.7) 122 (91.1) 116 (10.3) 13 (8.9) 0.714 No 87 (89.7) 122 (91.1) 0.006 10 (10.3) 10 (10.3) 10 (10.3) 0.001 No 87 (89.7) 122 (91.1) 0.006 10 (10.3) 0.001 <t< td=""><td>No</td><td>82 (84.5)</td><td>104 (77.0)</td><td></td></t<>	No	82 (84.5)	104 (77.0)	
Yes53 (54.6)86 (63.7)0.165No44 (45.4)49 (36.3)Diabetes (n, %)9 (9.3)19 (14.1)0.269No88 (90.7)116 (85.9)Time for surgery (median, hours)3.73.50.763Duration of verntlatory support (median, days)8.53.50.001Postoperative scizures (%)11 (10.3)13 (8.9)0.714No87 (89.7)122 (91.1)1Infection729 (21.5)<0.001	Hypertensive crisis $(n, \%)$			
No 44 (45.4) 49 (36.3) Diabetes (n, %) 3 $9 (9.3)$ $19 (14.1)$ 0.269 No $88 (90.7)$ $116 (68.5)$ 3.7 3.5 0.763 Duration of ventilatory support (median, days) 8.5 3.5 0.001 Postoperative seizures (%) $10 (10.3)$ $13 (8.9)$ 0.714 No $87 (89.7)$ $122 (91.1)$ 0.001 Infection $78 (84.5)$ $29 (21.5)$ <0.001 No $48 (49.5)$ $106 (78.5)$ <0.001 Cardiac failure ($n, \%$) $20 (20.6)$ $11 (8.1)$ 0.006 No $29 (21.5)$ <0.001 <0.001 No $48 (49.5)$ $106 (78.5)$ <0.001 Cardiac failure ($n, \%$) $24 (91.5)$ <0.001 <0.001 No $29 (21.5)$ <0.001 <0.001 No $29 (21.5)$ <0.001 <0.001 No $20 (20.6)$ $11 (8.1)$ <0.001 Setoperative cofFR 2	Yes	53 (54.6)	86 (63.7)	0.165
Diabetes $(n, \%)$ Yes 9 (9.3) 19 (14.1) 0.269 No 88 (90.7) 116 (85.9) 101 (85.9) Time for surgery (median, hours) 3.7 3.5 0.763 Duration of ventilatory support (median, days) 8.5 3.5 0.001 Postoperative scizures (%) 7 122 (91.1) 7 Yes 10 (10.3) 13 (8.9) 0.714 No 87 (89.7) 122 (91.1) 7 Infection 7 7 3.5 0.001 No 87 (89.7) 122 (91.1) 7 0.001 No 49 (50.5) 29 (21.5) <0.001	No	44 (45.4)	49 (36.3)	
Yes9 (9.3)19 (14.1)0.269No88 (90.7)116 (85.9)Time for surgery (median, hours)3.73.50.763Duration of ventilatory support (median, days)8.53.50.001Postoperative seizures (%)83.50.001Postoperative seizures (%)10 (10.3)13 (8.9)0.714No87 (97.7)122 (91.1)0.001Infection729 (21.5)<0.001	Diabetes $(n, \%)$			
No88 (90.7)116 (85.9)Time for surgery (median, hours) 3.7 3.5 0.763 Duration of ventilatory support (median, days) 8.5 3.5 0.001 Postoperative seizures (%) $10 (10.3)$ $13 (8.9)$ 0.714 No $87 (89.7)$ $122 (91.1)$ $116 (85.9)$ Infection $87 (89.7)$ $122 (91.1)$ $116 (85.9)$ Ves $49 (50.5)$ $29 (21.5)$ <0.001 No $48 (49.5)$ $106 (78.5)$ $Cardiac failure (n, %)$ Yes $20 (20.6)$ $11 (8.1)$ 0.006 No $77 (79.4)$ $124 (91.9)$ $CGFR (ml/min 1.73 m^2)$ Admission GGFR 91.9 ± 45.1 108.1 ± 45.7 <0.001 Postoperative eGFR 82.5 ± 42.2 106.5 ± 40.7 <0.001 3-day postoperative eGFR 73.5 ± 44.7 111.5 ± 46.6 <0.001 3-day postoperative eGFR 73.5 ± 42.2 0.6 ± 40.3 <0.001 3-day postoperative eGFR 36.1 ± 7.3 36.1 ± 7.0 0.753 TCO ₂ (mmHg) 36.1 ± 7.3 36.1 ± 7.0 0.753 TCO ₂ (mmHg) 24.1 ± 4.0 25.9 ± 3.4 <0.001 pH 7.41 ± 0.01 7.45 ± 0.04 <0.001 pH 7.41 ± 0.01 7.45 ± 0.04 <0.001 BE (mmol/L) 24.0 ± 3.1 25.8 ± 2.1 <0.001 BE (mmol/L) -1.2 ± 3.9 1.0 ± 2.7 <0.001 BE (mmol/L) -1.6 ± 4.4 0.8 ± 3.2 <0.001	Yes	9 (9.3)	19 (14.1)	0.269
Time for surgery (median, hours)3.73.50.763Duration of ventilatory support (median, days)8.53.50.001Postoperative seizures (%)Yes10 (10.3)13 (8.9)0.714No87 (89.7)122 (91.1)InfectionYes49 (50.5)29 (21.5)<0.001	No	88 (90.7)	116 (85.9)	
Duration of ventilatory support (median, days) 8.5 3.5 0.001 Postoperative seizures (%) 10 (10.3) 13 (8.9) 0.714 No 87 (89.7) 122 (91.1) 11 Infection 7 29 (21.5) <0.001	Time for surgery (median, hours)	3.7	3.5	0.763
Postoperative seizures (%) 10 (10.3) 13 (8.9) 0.714 No 87 (89.7) 122 (91.1) Infection 7 7 Yes 49 (50.5) 29 (21.5) <0.001	Duration of ventilatory support (median, days)	8.5	3.5	0.001
Yes10 (10.3)13 (8.9)0.714No87 (89.7)122 (91.1)Infection $Vgg(21.5)$ <0.001	Postoperative seizures (%)			
No $87 (89.7)$ $122 (91.1)$ InfectionYes49 (50.5) $29 (21.5)$ <0.001	Yes	10 (10.3)	13 (8.9)	0.714
Infection Yes 49 (50.5) 29 (21.5) <0.001	No	87 (89.7)	122 (91.1)	
Yes49 (50.5)29 (21.5)<0.001No48 (49.5)106 (78.5)Cardiac failure (n, %) Yes 20 (20.6)11 (8.1)0.006No77 (79.4)124 (91.9)eGFR (ml/min 1.73 m ²) Xes 91.9±45.1108.1±45.7<0.001	Infection			
No48 (49.5)106 (78.5)Cardiac failure (n, %)20 (20.6)11 (8.1)0.006No77 (79.4)124 (91.9)eGFR (ml/min 1.73 m²)477 (79.4)124 (91.9)Admission eGFR91.9±45.1108.1±45.7<0.001	Yes	49 (50.5)	29 (21.5)	< 0.001
Cardiac failure $(n, \%)$ Yes 20 (20.6) 11 (8.1) 0.006 No 77 (79.4) 124 (91.9) eGFR (ml/min 1.73 m ²) Admission eGFR 91.9±45.1 108.1±45.7 <0.001	No	48 (49.5)	106 (78.5)	
Yes20 (20.6)11 (8.1)0.006No77 (79.4)124 (91.9)eGFR (ml/min 1.73 m²) A dmission eGFR91.9±45.1108.1±45.7<0.001	Cardiac failure $(n, \%)$			
No $77 (79.4)$ $124 (91.9)$ eGFR (ml/min 1.73 m²)Admission eGFR 91.9 ± 45.1 108.1 ± 45.7 <0.001 Postoperative eGFR 82.5 ± 42.2 106.5 ± 40.7 <0.001 3-day postoperative eGFR 73.5 ± 44.7 111.5 ± 46.6 <0.001 7-day postoperative eGFR 75.2 ± 58.2 109.6 ± 46.3 <0.001 3-day postoperative ABG $FiO_2 (\%)$ 44.6 ± 13.1 41.7 ± 11.0 0.073 pCO_2 (mmHg) 36.1 ± 7.3 36.1 ± 7.0 0.753 TCO_2 (mmHg) 24.1 ± 4.0 25.9 ± 3.4 <0.001 pH 7.41 ± 0.01 7.45 ± 0.04 <0.001 HCO ₃ (mmol/L) 22.7 ± 4.3 24.8 ± 3.3 <0.001 BE (mmol/L) -1.2 ± 3.9 1.0 ± 2.7 <0.001 BE (mmol/L) -1.6 ± 4.4 0.8 ± 3.2 <0.001 Lactare (mmol/L) 2.0 ± 1.1 1.4 ± 0.5 <0.001	Yes	20 (20.6)	11 (8.1)	0.006
eGFR (ml/min 1.73 m²) $1000000000000000000000000000000000000$	No	77 (79.4)	124 (91.9)	
Admission eGFR 91.9 ± 45.1 108.1 ± 45.7 <0.001 Postoperative eGFR 82.5 ± 42.2 106.5 ± 40.7 <0.001 3 -day postoperative eGFR 73.5 ± 44.7 111.5 ± 46.6 <0.001 7 -day postoperative eGFR 75.2 ± 58.2 109.6 ± 46.3 <0.001 3 -day postoperative ABG 52 ± 58.2 109.6 ± 46.3 <0.001 3 -day postoperative ABG 52 ± 58.2 109.6 ± 46.3 <0.001 3 -day postoperative ABG 52 ± 58.2 109.6 ± 46.3 <0.001 pCO_2 (mmHg) 36.1 ± 7.3 36.1 ± 7.0 0.753 TCO_2 (mmHg) 24.1 ± 4.0 25.9 ± 3.4 <0.001 pH 7.41 ± 0.01 7.45 ± 0.04 <0.001 HCO_{3} (mmol/L) 22.7 ± 4.3 24.8 ± 3.3 <0.001 HCO_{3std} (mmol/L) 24.0 ± 3.1 25.8 ± 2.1 <0.001 BE (mmol/L) -1.2 ± 3.9 1.0 ± 2.7 <0.001 BEcef (mmol/L) -1.6 ± 4.4 0.8 ± 3.2 <0.001 Lactate (mmol/L) 2.0 ± 1 1.4 ± 0.5 <0.001	eGFR (ml/min 1.73 m ²)			
Postoperative eGFR 82.5 ± 42.2 106.5 ± 40.7 <0.001 3-day postoperative eGFR 73.5 ± 44.7 111.5 ± 46.6 <0.001 7-day postoperative eGFR 75.2 ± 58.2 109.6 ± 46.3 <0.001 3-day postoperative ABG FiO_2 (%) 44.6 ± 13.1 41.7 ± 11.0 0.073 pCO_2 (mmHg) 36.1 ± 7.3 36.1 ± 7.0 0.753 TCO_2 (mmHg) 24.1 ± 4.0 25.9 ± 3.4 <0.001 pH 7.41 ± 0.01 7.45 ± 0.04 <0.001 HCO_3^- (mmol/L) 22.7 ± 4.3 24.8 ± 3.3 <0.001 HCO_{3std} (mmol/L) 24.0 ± 3.1 25.8 ± 2.1 <0.001 BE (mmol/L) -1.2 ± 3.9 1.0 ± 2.7 <0.001 Lactate (mmol/L) -1.6 ± 4.4 0.8 ± 3.2 <0.001	Admission eGFR	91.9±45.1	108.1 ± 45.7	< 0.001
3-day postoperative eGFR73.5 \pm 44.7111.5 \pm 46.6<0.0017-day postoperative eGFR75.2 \pm 58.2109.6 \pm 46.3<0.001	Postoperative eGFR	82.5±42.2	106.5 ± 40.7	< 0.001
The first of the second se	3-day postoperative eGFR	73.5+44.7	111.5±46.6	< 0.001
3-day postoperative ABG 44.6±13.1 41.7±11.0 0.073 $pCO_2 (mmHg)$ 36.1±7.3 36.1±7.0 0.753 $TCO_2 (mmHg)$ 24.1±4.0 25.9±3.4 <0.001	7-day postoperative eGFR	75.2±58.2	109.6±46.3	< 0.001
FiO2 (%) 44.6 ± 13.1 41.7 ± 11.0 0.073 pCO2 (mmHg) 36.1 ± 7.3 36.1 ± 7.0 0.753 TCO2 (mmHg) 24.1 ± 4.0 25.9 ± 3.4 <0.001 pH 7.41 ± 0.01 7.45 ± 0.04 <0.001 HCO3 (mmol/L) 22.7 ± 4.3 24.8 ± 3.3 <0.001 HCO3 (mmol/L) 24.0 ± 3.1 25.8 ± 2.1 <0.001 BE (mmol/L) -1.2 ± 3.9 1.0 ± 2.7 <0.001 BEecf (mmol/L) -1.6 ± 4.4 0.8 ± 3.2 <0.001	3-day postoperative ABG			
$pCO_2 (mmHg)$ 36.1 ± 7.3 36.1 ± 7.0 0.753 $TCO_2 (mmHg)$ 24.1 ± 4.0 25.9 ± 3.4 <0.001 pH 7.41 ± 0.01 7.45 ± 0.04 <0.001 $HCO_3^- (mmol/L)$ 22.7 ± 4.3 24.8 ± 3.3 <0.001 $HCO_{3std} (mmol/L)$ 24.0 ± 3.1 25.8 ± 2.1 <0.001 $HCO_{3std} (mmol/L)$ -1.2 ± 3.9 1.0 ± 2.7 <0.001 $BEecf (mmol/L)$ -1.6 ± 4.4 0.8 ± 3.2 <0.001 $Lactate (mmol/L)$ 2.0 ± 1.1 1.4 ± 0.5 <0.001	$FiO_{(\%)}$	44.6±13.1	41.7 ± 11.0	0.073
FCO_2 (mmHg) 24.1 ± 4.0 25.9 ± 3.4 <0.001 pH 7.41 ± 0.01 7.45 ± 0.04 <0.001 HCO_3^{-} (mmol/L) 22.7 ± 4.3 24.8 ± 3.3 <0.001 HCO_{3std} (mmol/L) 24.0 ± 3.1 25.8 ± 2.1 <0.001 BE (mmol/L) -1.2 ± 3.9 1.0 ± 2.7 <0.001 BEecf (mmol/L) -1.6 ± 4.4 0.8 ± 3.2 <0.001 Lactate (mmol/L) 2.0 ± 1.1 1.4 ± 0.5 <0.001	pCO ₂ (mmHg)	36.1±7.3	36.1±7.0	0.753
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	TCO (mmHg)	24.1±4.0	25.9+3.4	< 0.001
HCO_3^- (mmol/L) 22.7 ± 4.3 24.8 ± 3.3 <0.001 HCO_{3std} (mmol/L) 24.0 ± 3.1 25.8 ± 2.1 <0.001 BE (mmol/L) -1.2 ± 3.9 1.0 ± 2.7 <0.001 $BEecf$ (mmol/L) -1.6 ± 4.4 0.8 ± 3.2 <0.001 Lactate (mmol/L) 2.0 ± 1.1 1.4 ± 0.5 <0.001	nH	7.41±0.01	7.45±0.04	< 0.001
HCO _{3std} (mmol/L) 24.0±3.1 25.8±2.1 <0.001 BE (mmol/L) -1.2±3.9 1.0±2.7 <0.001	HCO, (mmol/L)	22.7±4.3	24.8±3.3	< 0.001
BE (mmol/L) -1.2±3.9 1.0±2.7 <0.001 BEecf (mmol/L) -1.6±4.4 0.8±3.2 <0.001	HCO, (mmol/L)	24.0±3.1	25.8±2.1	< 0.001
BEecf (mmol/L) -1.6±4.4 0.8±3.2 <0.001	BE (mmol/L)	-1.2±3.9	1.0±2.7	<0.001
Lactate (mmol/L) 20+11 14+05 <0.001	BEecf (mmol/L)	-1.6±4.4	0.8±3.2	< 0.001
Lucius (Innor 1) 2.9-1.1 1.7-0.2 50.001	Lactate (mmol/L)	2.0±1.1	$1.4{\pm}0.5$	< 0.001

ICH, intracranial hemorrhage, GCS, Glasgow Coma Scale, eGFR, estimated glomerular filtration rate, ABG, arterial blood gas analysis, V-SIMV (volumesynchronized intermittent mandatory ventilation) or P-SIMV (pressure-synchronized intermittent mandatory ventilation) for sedated patients. For patients who were spontaneously breathing, we employed CPAP (continuous positive airway pressure) or PSV (pressure support ventilation), PH, pondus hydrogenii, BE, base excess, BEecf, extracellular fluid base excess, TCO₂, total partial pressure of carbon dioxide, HCO_{3std}, standard HCO₃

The prevalence of obesity (body mass index ≥ 28), diabetes, and hypertension crisis was also similar in both subgroups (all P > 0.05, Table 1).

However, patients with a bleak prognosis (OS <3 months) exhibited certain distinct characteristics compared to those with a more favorable prognosis. Specifically, the group A

cases had lower admission GCS scores (mean for group A and B cases: 6.0 ± 3.1 vs. 9.1 ± 3.5 , P < 0.001), larger hematoma volumes (mean for group A and B cases: 52.8 ± 31.8 vs. 33.3 ± 25.1 ml, P = 0.002), a higher incidence of ventricular intrusion (52.6% vs. 25.2%, P < 0.001), infection (50.5% vs. 21.5%, P < 0.001), and a higher prevalence of cardiac failure (20.6% vs. 8.1%, P = 0.006).

Importantly, we observed a substantial difference in kidney function between these two subgroups. The admission eGFR for group A cases was significantly lower compared to group B cases (91.9 ± 45.1 vs. 108.1 ± 45.7 ml/min \cdot 1.73 m², *P* < 0.001). This finding suggests that a good reserve of kidney function may be crucial for the prognosis of hypertension-related ICH cases undergoing surgical intervention. Overall, these results indicate that factors such as lower GCS scores, larger hematoma volumes, ventricular intrusion, cardiac failure, and impaired kidney function are associated with poorer outcomes in patients who underwent surgical intervention due to hypertension-related ICH cases.

Distinct dynamic kidney function changes were observed in 3-month dead and alive cases

We collected eGFR data at four-time points in this case set, revealing distinct dynamic trends among the subgroups [Figure 2a and Table 1]. In group A, there was a substantial worsening of eGFR from admission to postoperative, 3-day postoperative, and 7-day postoperative time points (mean values: 91.9 ± 45.1 , 82.5 ± 42.2 , 73.5 ± 44.7 , 75.2 ± 58.2 ml/

min $\cdot 1.73 \text{ m}^2$, respectively). In contrast, no significant change in eGFR was observed in group B (mean values: 108.1 ± 45.7 , 106.5 ± 40.7 , 111.5 ± 46.6 , $109.6 \pm 46.3 \text{ ml/min} \cdot 1.73 \text{ m}^2$, respectively). These findings suggest that during the treatment of patients who underwent surgical intervention due to hypertension-related ICH, certain treatments may have adverse effects on kidney function, particularly in patients with limited reserves. Furthermore, we performed ROC analysis to evaluate the prognostic significance of eGFR at different time points. The results revealed that the eGFR at the 3-day postoperative time point had the highest prognostic predictive value in this case set (AUC for admission, postoperative, 3-day postoperative, and 7-day postoperative: 0.617, 0.675, 0.737, 0.730, Figure 2b).

Based on these findings, we utilized the 3-day postoperative eGFR instead of the admission eGFR for subsequent survival analysis, as it demonstrated superior prognostic accuracy.

Disturbed acid-base equilibrium was closely associated with insufficient kidney function

The kidney plays a vital role in maintaining acid-base equilibrium by regulating the secretion of hydrogen ions (H^+). Given the substantial difference in 3-day eGFR between groups A and B, we further investigated the acid-base equilibrium balance in these two subgroups. We observed imbalances in several acid-base parameters, indicating disrupted equilibrium.

In patients with a bleak prognosis (3-month dead subgroup), we observed lower pH values (mean for dead and alive patients:



Figure 2: Patients were divided into group A ($OS \le 3$ months) and group B (OS > 3 months) to determine factors correlative with survival. (a) The eGFR substantially worsened in group A (mean for admission, postoperative, 3-day postoperative, and 7-day postoperative: 91.9 ± 45.1 , 82.5 ± 42.2 , 73.5 ± 44.7 , 75.2 ± 58.2 ml/min 1.73 m², respectively), while no significant change was observed in group B (mean for admission, postoperative, 3-day postoperative, and 7-day postoperative; 108.1 ± 45.7 , 106.5 ± 40.7 , 111.5 ± 46.6 , 109.6 ± 46.3 ml/min 1.73 m², respectively). (b) ROC curves revealed that the 3-day eGFR was the best prognostic predictor in this case set (AUC for enrollment, postoperative, 3-day postoperative; 0.617, 0.675, 0.737, 0.730). c-f, Lower PH (group A and B, 7.41 ± 0.01 vs. 7.45 ± 0.04 , P < 0.001, c-a), higher lactate (2.0 ± 1.1 vs. 1.4 ± 0.5 mmol/L, P < 0.001, c-b), lower BE (-1.2 ± 3.9 vs. 1.0 ± 2.7 mmol/L, P < 0.001, d-a) and BEecf (-1.6 ± 4.4 vs. 0.8 ± 3.2 mmol/L, P < 0.001, d-b), lower TCO2 (24.1 ± 4.0 vs. 25.9 ± 3.4 mmHg, P < 0.001, e-b) instead of pCO2 (36.1 ± 7.3 vs. 36.1 ± 7.0 mmHg, P = 0.753, e-a), and lower HCO3⁻ (22.7 ± 4.3 vs. 24.8 ± 3.3 mmol/L, P < 0.001, f-a) and HCO₃std⁻ (24.0 ± 3.1 vs. 25.8 ± 2.1 mmol/L, P < 0.001, f-b) in group A revealed comprehensive out-of-regulation for acid-base equilibrium, which could intensify the brittle homeostasis and lead to death. Abbreviations: eGFR, estimated glomerular filtration rate, PH, pondus hydrogenii, BE, base excess, BEecf, extracellular fluid base excess, TCO2, total partial pressure of carbon dioxide, HCO3_{std}⁻, standard HCO3⁻

7.41 ± 0.01 vs. 7.45 ± 0.04, P < 0.001, Figure 2c-a), higher lactate levels (2.0 ± 1.1 vs. 1.4 ± 0.5 mmol/L, P < 0.001, Figure 2c-b), lower base excess (BE) levels (-1.2 ± 3.9 vs. 1.0 ± 2.7 mmol/L, P < 0.001, Figure 2d-a) and extracellular fluid base excess (BEecf) levels (-1.6 ± 4.4 vs. 0.8 ± 3.2 mmol/L, P < 0.001, Figure 2d-b), lower total partial pressure of carbon dioxide (TCO₂) levels (24.1 ± 4.0 vs. 25.9 ± 3.4 mmHg, P < 0.001, Figure 2e-b) but similar partial pressure of carbon dioxide (pCO₂) levels (36.1 ± 7.3 vs. 36.1 ± 7.0 mmHg, P = 0.753, Figure 2e-a), as well as lower bicarbonate (HCO3⁻) levels (22.7 ± 4.3 vs. 24.8 ± 3.3 mmol/L, P < 0.001, Figure 2f-a) and standard bicarbonate (HCO3std⁻) levels (24.0 ± 3.1 vs. 25.8 ± 2.1 mmol/L, P < 0.001, Figure 2f-b).

These findings collectively indicate comprehensive dysregulation of acid-base equilibrium in the 3-month dead subgroup. Such imbalances can further disrupt homeostasis and potentially contribute to fatal outcomes.

Survival analysis demonstrated the hierarchy of kidney function as an independent prognosis risk factor

With a median follow-up period of 15.0 months, a total of 137 (59.1%) ICH cases in our study population had succumbed, resulting in a median OS of 10.0 months. Several adverse factors were identified as predictors of survival, including advanced age, low GCS score (3–8), ventricle intrusion of hematomas, cardiac failure, long duration of ventilatory support (>6 days), infection, larger hematoma volume (>35.34 ml), and lower 3-day postoperative GFR. These findings are summarized in Table 2. In the multivariate analysis, low GCS score, infection, cardiac failure, larger hematoma volume, and lower 3-day postoperative GFR remained significant predictors of survival [Table 2 and Figure 3a].

Although the Glasgow Outcome Scale (GOS) scores were effective in predicting hierarchical outcomes for this case set [Figure 3b], the lag in GOS assessment made it less ideal as a prognostic factor. Instead, we employed GCS scores, which provided a more timely and precise prediction. Additionally, the 3-day postoperative eGFR demonstrated efficient predictive capability for outcomes in hypertensive ICH cases, and a clear inverse correlation was observed between kidney function stage and OS [Figure 3c].

To further enhance prognostic prediction, we developed a nomogram model that incorporated GCS score, cardiac failure, hematoma volume, infection, and lower 3-day postoperative eGFR. The nomogram highlighted the crucial importance of the 3-day eGFR in predicting OS [Figure 4a]. By assigning scores to each parameter, we were able to accurately assess the 1-year probabilities. Calibration plots demonstrated good agreement between the observed fraction survival probability and the nomogram-estimated survival probability [Figure 4b]. Furthermore, the DCA confirmed the predictive capacity of the model, affirming the significance of all the key characteristics [Figure 4c].

DISCUSSION

The acute phase of hypertensive ICH is often accompanied by kidney failure or the worsening of existing compromised renal reserves,^[18,19] especially for surgically treated cases. The development of oliguria and anuria due to kidney failure can ultimately lead to refractory and potentially fatal fluid and electrolyte imbalances, as well as disturbances in acid-base equilibrium.^[20] Therefore, recognizing the critical role of kidney function in managing patients who undergo surgical intervention for hypertension-related ICH is crucial



Figure 3: Survival analysis for hypertensive ICH cases who underwent surgical intervention. (a) the low GCS score, ventricle intrusion of the hematoma, heart failure, infection, larger hematoma volume, and lower 3-day postoperative eGFR were independent risk factors for overall survival in multivariate analysis. (b) Though GOS scores could effectively and precisely predict hierarchal outcomes for this set [Figure 2b], the hysteresis of GOS assessment rendered it an unideal factor to predict prognosis and we employed GCS scores instead. (c) the 3-day postoperative eGFR could also efficiently predict outcomes for hypertensive ICH cases and an inverse correlation was observed between kidney function stage and OS

Table 2: Cox hazards regression	analysis for patie	ents who underwent surg	ery due to hy	pertension-related ICH o	f OS	
Characteristics	Total (<i>n</i> ,%)	Univariate anal	ysis	Multivariate analysis		
		HR (95% CI)	Р	HR (95% CI)	Р	
Age	232 (100)	1.015 (1.002–1.029)	0.028	1.004 (0.992–1.017)	0.468	
Gender	232 (100)					
Male	160 (69.0)	Reference				
Female	72 (31.0)	0.950 (0.662-1.363)	0.779			
GCS score	232 (100)					
13–15	26 (11.2)	Reference				
9–12	67 (28.9)	1.358 (0.612-3.014)	0.452	2.261 (0.992-5.157)	0.053	
3–8	139 (59.9)	4.179 (2.027-8.616)	< 0.001	5.235 (2.469–11.272)	< 0.001	
Ventricle intrusion	232 (100)					
No	147 (63.4)	Reference				
Yes	85 (36.7)	1.926 (1.374-2.700)	< 0.001	1.404 (0.985-2.002)	0.041	
Obesity	232 (100)					
Yes	46 (19.8)	Reference				
No	186 (80.2)	1.395 (0.884-2.202)	0.153			
Hypertension crisis	232 (100)					
No	139 (59.9)	Reference				
Yes	93 (40.1)	1.280 (0.913-1.795)	0.153			
Diabetes	232 (100)					
No	204 (87.9)	Reference				
Yes	28 (12.1)	0.818 (0.479-1.399)	0.464			
Cardiac failure	232 (100)					
No	201 (86.7)	Reference				
Yes	31 (13.3)	2.258 (1.470-3.469)	< 0.001	2.852 (1.886-3.272)	< 0.001	
Duration of ventilatory support (days)	× /					
≤6	118 (50.9)	Reference				
>6	114 (49.1)	1.571 (1.116-2.212)	< 0.010	1.546 (0.998-2.018)	0.053	
Infection						
No	154 (66.4)	Reference				
Yes	78 (33.6)	3.689 (2.156-5.278)	< 0.001	3.536 (3.125-5.065)	< 0.001	
Hematoma volume (ml)	232 (100)					
<35.34	117 (50.4)	Reference				
>35.34	115 (49.6)	2.594 (1.827-3.682)	< 0.001	1.572 (1.091-2.411)	0.017	
3-day eGFR (ml/min 1.73 m ²)	232 (100)					
≥90	118 (50.9)	Reference				
60–89	57 (24.6)	2.640 (1.735-4.016)	< 0.001	3.001 (1.324-4.300)	< 0.001	
30–59	43 (18.5)	4.518 (2.927-6.973)	< 0.001	3.263 (2.162-4.213)	< 0.001	
15–29	10 (4.3)	3.193 (1.439-7.085)	0.004	2.631 (1.231-5.065)	0.031	
<15	4 (1.7)	7.718 (2.733–21.793)	< 0.001	5.586 (2.651-11.256)	< 0.001	

ICH, intracranial hemorrhage

for guiding treatment planning. Our study results indicate that preserving adequate kidney function is of paramount importance in dealing with the acute phase of ICH for surgically treated patients. It is important to note that the treatment of ICH itself can exacerbate kidney dysfunction or even lead to renal failure, resulting in unfavorable outcomes. Therefore, protecting kidney function should be carefully considered to promote more favorable outcomes in surgically treated patients.

By identifying the significant association between kidney function and prognosis, our study highlights the need to incorporate renal assessment and preservation strategies into the management of patients with surgically treated hypertension-related ICH. Strategies aimed at minimizing the potential negative impact of ICH treatments on kidney function, such as adjusting dosages, utilizing alternative medications, or implementing supportive measures, should be considered. Additionally, close monitoring of renal function parameters, including GFR and acid-base balance, should be an integral part of the clinical management plan.

Further research is warranted to explore the underlying mechanisms linking kidney function and ICH outcomes in surgically treated patients. Understanding the intricate interplay between renal dysfunction and the pathophysiology of ICH could potentially lead to the development of targeted interventions and improved therapeutic strategies.



Figure 4: Nomogram model for predicting OS in hypertensive ICH cases who underwent surgical intervention. (a) A nomogram model incorporating GCS score, ventricle intrusion of hematoma, heart failure, hematoma volume, lower 3-day postoperative eGFR, and infection to assess survival probability and the nomogram showed the vital importance of 3-day eGFR in predicting OS (b) calibration plots graphically showed good agreement between the observed fraction survival probability and the nomogram-estimated survival probability. (c) The DCA analysis assessed the model endowing all the crucial characteristics with satisfying predicting capacity

By prioritizing the preservation of kidney function in the management of surgically treated hypertension-related ICH, we can strive for better patient outcomes and a more comprehensive approach to care.

Dehydration treatment, particularly the use of mannitol, plays a crucial role in reducing cerebral edema caused by hematomas.^[21,22] However, it is important to recognize that mannitol can have adverse effects on kidney function.[23,24] Our study revealed a persistent decline in eGFR among patients with poor prognosis, indicating a correlation between mannitol usage and kidney function deterioration. High doses of mannitol can lead to constriction of the glomerular arterioles, resulting in reduced renal blood flow and subsequent kidney dysfunction or failure.^[23,24] It is acknowledged that mannitol can cause osmotic diuresis, which may result in a temporary decrease in eGFR. This diuretic effect can potentially lead to an acute decline in renal function. Moreover, mannitol has been associated with other renal effects, such as alterations in tubular function and electrolyte imbalances. These factors suggest a plausible relationship between mannitol administration and reduced eGFR in our study population. Therefore, careful monitoring of kidney function is essential during the treatment of ICH. Consideration should be given to reducing or discontinuing mannitol administration, and alternative options such as furosemide or glycerin fructose may be considered to address cerebral edema.

Patients with diabetes often experience structural changes in the glomerulus due to long-term hyperglycemia and insulin hyposecretion.^[25-28] These changes include a reduction in heparan sulfate glycoproteins in the basement membrane and a deficiency of negative charges, leading to impaired kidney function.^[28] In our study, although the number of patients with diabetes was limited (27/232, 11.6%), it is important to carefully monitor and manage blood glucose levels to promote wound healing and protect kidney function in these individuals.

Advanced age is frequently accompanied by comorbidities such as hypertension, diabetes, and cardiac insufficiency.^[29] The compensatory capacity of elderly patients is often compromised due to aging and the cumulative effects of these diseases. Consequently, these factors contribute to acute kidney failure and poorer prognosis in surgically treated ICH patients. Univariate analysis revealed that age was a risk factor for poor prognosis, highlighting the need for increased attention and individualized treatment protocols for these patients.

A significant portion of the patients in our study presented with surgically treated hypertensive ICH and a deep coma status (GCS score ≤ 8) (54.7%, 127/232). This subgroup experienced more disease manifestations, including larger hemorrhage volumes, ventricle intrusion, and advanced age. The sudden and massive intracranial bleeding directly leads to increased intracranial pressure and profound neuroendocrine changes, resulting in vasoconstriction and inadequate renal blood perfusion. Additionally, factors such as intractable vomiting, gastrointestinal bleeding, insufficient fluid intake, and the use of dehydrating agents further exacerbate blood volume depletion and can ultimately lead to circulatory failure.^[30] These pathological changes collectively contribute to the compromised renal blood supply. Moreover, the dose of mannitol usage positively correlates with the severity of ICH, indicating a more pronounced impact on kidney function in patients with lower GCS scores.

Furthermore, we identified cardiac failure, larger hematoma volume, and ventricle intrusion as independent adverse factors for overall survival. The neuroendocrine and circulatory alterations associated with hypertensive ICH increase the risk of cardiovascular events, particularly in patients with insufficient functional reserves. Larger hematoma volume and ventricle intrusion can lead to life-threatening cerebral herniation, acute obstructive hydrocephalus, and delayed vasospasm, ultimately resulting in respiratory and circulatory failure.^[30-32] Therefore, protecting cardiac function is crucial in the context of surgically treated hypertensive ICH to enhance patient survival.

There are limitations to consider in our study, primarily due to its retrospective design and single-center nature, which introduce the possibility of selection bias. Additionally, the variation in post-discharge rehabilitation and supportive care provided to the patients may have influenced survival outcomes. Factors such as blood pressure control, timing of craniectomy, duration of hospital stay, duration of ventilatory support, and occurrence of postoperative seizures can influence the outcomes of patients. Despite these limitations, our study provides valuable insights into the assessment of kidney function in patients with hypertensive ICH and highlights impaired renal function as an adverse prognostic factor. Further research is warranted.

CONCLUSION

For patients with hypertensive intracerebral hemorrhage (ICH), the protection of kidney function is of paramount importance in the pursuit of favorable prognoses. Impaired 3-day postoperative glomerular filtration rate (eGFR) was identified as an independent risk factor for overall survival. Moreover, the use of furosemide or glycerin fructose as alternatives to mannitol can safely lower intracranial pressure and alleviate cerebral edema. By prioritizing the preservation of kidney function and implementing appropriate treatment strategies, healthcare professionals can contribute to improving the prognoses of patients with hypertensive ICH.

Acknowledgment

The authors sincerely thank the patients and their families for their participation in the present study.

Authors' contributions

Literature search, study design, data collection, data interpretation, writing: Jian Wang, Rui Wang, Hu Qin, Lei Zuo

Data availability

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Xinjiang Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was waived by the Institutional Review Board.

Abbreviations

ICH, intracranial hemorrhage, GCS, Glasgow Coma Scale, GOS, Glasgow Outcome Scale, OS, overall survival, eGFR, estimated glomerular filtration rate, ABG, arterial blood gas analysis, PH, pondus hydrogenii, BE, base excess, BEecf, extracellular fluid base excess, TCO₂, total partial pressure of carbon dioxide, HCO3_{etf}, standard HCO3⁻

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, *et al.* 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: A guideline from the American Heart Association/American Stroke Association. Stroke 2022;53:e282-361.
- Veltkamp R, Purrucker J. Management of spontaneous intracerebral hemorrhage. Curr Neurol Neurosci Rep 2017;17:80.
- Hostettler IC, Seiffge DJ, Werring DJ. Intracerebral hemorrhage: An update on diagnosis and treatment. Expert Rev Neurother 2019;19:679-94.
- Kim JY, Bae HJ. Spontaneous intracerebral hemorrhage: Management. J Stroke 2017;19:28-39.
- Kearns KN, Ironside N, Park MS, Worrall BB, Southerland AM, Chen CJ, *et al*. Neuroprotective therapies for spontaneous intracerebral hemorrhage. Neurocrit Care 2021;35:862-86.
- Ironside N, Chen CJ, Ding D, Mayer SA, Connolly ES Jr. Perihematomal edema after spontaneous intracerebral hemorrhage. Stroke 2019;50:1626-33.
- Magid-Bernstein J, Girard R, Polster S, Srinath A, Romanos S, Awad IA, *et al.* Cerebral hemorrhage: Pathophysiology, treatment, and future directions. Circ Res 2022;130:1204-29.
- Schrag M, Kirshner H. Management of intracerebral hemorrhage: JACC focus seminar. J Am Coll Cardiol 2020;75:1819-31.
- An SJ, Kim TJ, Yoon BW. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: An update. J Stroke 2017;19:3-10.
- Bereczki D, Fekete I, Prado GF, Liu M. Mannitol for acute stroke. Cochrane Database Syst Rev 2007;2007:Cd001153. doi: 10.1002/14651858.CD001153.pub2.
- 11. Sun S, Li Y, Zhang H, Wang X, She L, Yan Z, *et al.* The effect of mannitol in the early stage of supratentorial hypertensive intracerebral hemorrhage: A systematic review and meta-analysis. World Neurosurg2018:S1878-8750(18)32818-3. doi: 10.1016/j.wneu. 2018.11.249.
- Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF. Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc 2005;80:420-33.
- Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, *et al.* The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996;27:1304-5.

- Stevens PE, Levin A. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158:825-30.
- 15. Soveri I, Berg UB, Björk J, Elinder CG, Grubb A, Mejare I, *et al.* Measuring GFR: A systematic review. Am J Kidney Dis 2014;64:411-24.
- Freeman WD, Aguilar MI. Intracranial hemorrhage: Diagnosis and management. Neurol Clin 2012;30:211-40, i×.
- Dastur CK, Yu W. Current management of spontaneous intracerebral haemorrhage. Stroke Vasc Neurol 2017;2:21-9.
- Nadkarni GN, Patel AA, Konstantinidis I, Mahajan A, Agarwal SK, Kamat S, *et al.* Dialysis requiring acute kidney injury in acute cerebrovascular accident hospitalizations. Stroke 2015;46:3226-31.
- Saeed F, Adil MM, Piracha BH, Qureshi AI. Acute renal failure worsens in-hospital outcomes in patients with intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2015;24:789-94.
- Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purif 2017;43:179-88.
- Gao B, Gu H, Yu W, Liu S, Zhou Q, Kang K, *et al.* Admission dehydration is associated with significantly lower in-hospital mortality after intracerebral hemorrhage. Front Neurol 2021;12:637001.
- Lehmann F, Schenk LM, Bernstock JD, Bode C, Borger V, Gessler F, et al. Admission dehydration status portends adverse short-term mortality in patients with spontaneous intracerebral hemorrhage. J Clin Med 2021;10:5939.

- Tan G, Zhou J, Yuan D, Sun S. Formula for use of mannitol in patients with intracerebral haemorrhage and high intracranial pressure. Clin Drug Investig 2008;28:81-7.
- 24. Kim MY, Park JH, Kang NR, Jang HR, Lee JE, Huh W, *et al.* Increased risk of acute kidney injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage. J Neurosurg 2014;120:1340-8.
- Samsu N. Diabetic nephropathy: Challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int 2021;2021:1497449.
- Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013;124:139-52.
- 27. Bloomgarden ZT. Diabetic nephropathy. Diabetes Care 2005;28:745-51.
- Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010;21:556-63.
- Wilkinson DA, Pandey AS, Thompson BG, Keep RF, Hua Y, Xi G. Injury mechanisms in acute intracerebral hemorrhage. Neuropharmacology 2018;134:240-8.
- Garton T, Hua Y, Xiang J, Xi G, Keep RF. Challenges for intraventricular hemorrhage research and emerging therapeutic targets. Expert Opin Ther Targets 2017;21:1111-22.
- Monteagudo A. Intracranial hemorrhage. Am J Obstet Gynecol 2020;223:B34-7.
- Nelson SE, Mould WA, Gandhi D, Thompson RE, Salter S, Dlugash R, et al. Primary intraventricular hemorrhage outcomes in the CLEAR III trial. Int J Stroke 2020;15:872-80.